We are live on
!
Find out more
Antipodes Partners Portfolio holdings
AUM
$5.46B
Turnover
36.94%
1-Year Est. Return
26.64%
This Fund
S&P 500
This Quarter
Est. Return
+4.16%
1 Year Est. Return
+26.64%
3 Year Est. Return
+96.4%
5 Year Est. Return
+160.76%
10 Year Est. Return
–
AUM
$5.46B
AUM Growth
+$264M
(+5.1%)
Cap. Flow
+$147M
Cap. Flow
% of AUM
2.69%
Top 10 Holdings %
Top 10 Hldgs %
33.99%
Holding
157
New
31
Increased
42
Reduced
55
Closed
27
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
1.6
years
Top 20 Avg Time Held Equity + Options
2
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
1.6
years
Top 20 Avg Time Held Equity only
2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$90.4M |
| 2 |
Qorvo
QRVO
|
+$75.2M |
| 3 |
Meta Platforms (Facebook)
META
|
+$52.4M |
| 4 |
NVIDIA
NVDA
|
+$45.8M |
| 5 |
Capital One
COF
|
+$42.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Workday
WDAY
|
+$59M |
| 2 |
Microsoft
MSFT
|
+$55.4M |
| 3 |
Amazon
AMZN
|
+$50.3M |
| 4 |
Merck
MRK
|
+$40.2M |
| 5 |
Oracle
ORCL
|
+$31.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Utilities | 27.87% |
| 2 | Technology | 14.3% |
| 3 | Healthcare | 11.52% |
| 4 | Consumer Discretionary | 9.78% |
| 5 | Energy | 8.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
Tarsus Pharmaceuticals
TARS
$3.32B
| – | – |
-555
| Closed | -$38.9K | – |
|
152
DELISTED
Terns Pharmaceuticals
TERN
| – | – |
-455
| Closed | -$24K | – |
|
153
Teva Pharmaceutical Industries Limited
TEVA
$47.9B
| – | – |
-2,234
| Closed | -$67.3K | – |
|
154
VNET Group
VNET
$1.26B
| – | – |
-13,915
| Closed | -$117K | – |
|
155
Viridian Therapeutics
VRDN
$2.22B
| – | – |
-834
| Closed | -$16.3K | – |
|
156
BioAge Labs
BIOA
$246M
| – | – |
-915
| Closed | -$16K | – |
|
157
Power Solutions International
PSIX
$1.17B
| – | – |
-52,877
| Closed | -$3.22M | – |
|
Similar funds
SCM
Antipodes Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Antipodes Partners held 157 positions worth $5.46B, up 5.1% from $5.19B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
Antipodes Partners's Q2 2026 filing shows 31 new, 42 increased, 55 reduced and 27 closed positions. Its largest new stake was Booking.com: 530,062 shares worth $94.2M. The largest sale was Workday, an estimated $59M.
By sector, the portfolio is most concentrated in Utilities at 28% of assets, down from 29% a quarter earlier, followed by Technology and Healthcare.
- Antipodes Partners's largest Q2 2026 buy was Booking.com: 530,062 shares worth $94.2M.
- Antipodes Partners added most to Meta Platforms (Facebook) in Q2 2026, an estimated $52.4M increase.
- Antipodes Partners's biggest Q2 2026 reduction was Workday, cutting an estimated $59M.
- Antipodes Partners fully exited Oracle in Q2 2026, selling an estimated $31.2M.
- Antipodes Partners's ten largest holdings make up 34% of its $5.46B portfolio in Q2 2026.
- Antipodes Partners opened 31 new positions and closed 27 in Q2 2026.
- Antipodes Partners's portfolio value rose 5.1% quarter-over-quarter to $5.46B.
Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.